Graham Randall, Phd, Mba Email & Phone Number

Austin, Texas, Us

Galveston, Tx, Us

Galveston, Tx, Us

As CEO of Noninvasix, I grew the company by 10X. I was selected to participate in 3 accelerator programs by Philips (Philips Healthworks), Johnson & Johnson Innovation (JLABS), and Texas Medical Center (TMC|X). I spent an intensive 3 months in Philips’ accelerator program, on-site in Eindhoven, understanding how to commercialize R&D and successfully launch products to the market. Backed by guidance and investment from Philips, I positioned Noninvasix for growth. In addition to raising over $7M for the company in investments and grants, I focused on building a solid foundation for the organization:• Worked closely with engineering team to deliver alpha-prototype of world’s first non-invasive central venous oximeter and conduct human clinical testing of oxygenation monitoring devices• Managed worldwide (US, EU, Canada, Australia, Japan, and China) IP portfolio with 30 issued patents• Led five FDA submissions and three in-person meetings with the FDA in partnership with regulatory consultant• Negotiated both Breakthrough Device Designation and de novo 510(k) regulatory pathway with FDA • Developed new signal processing algorithm (in Python using NumPy and SciPy) to enable oximeter to measure oxygenation in deep blood vessels• Oversaw custom development of pulsed laser diode subsystem in partnership with engineering team and laser vendor

Galveston, Tx, Us

Houston, Tx, Us

Sola is a new, all-natural, low calorie, low carb, sugar substitute. After developing the business plan with the inventor, I was able to position the company for growth by:• Securing $8M in funding from a family office• Recruiting a team of high-performing executives from Splenda, Imperial Sugar, and Borden Foods to finalize the formulation, marketing strategy, sales strategy, and operating plan for Sola• Preparing the product for launch to national and local retailers including Costco, Walmart, Kroger, and H-E-B

Arcos is a healthcare IT startup commercializing clinical decision support technology from US Army Institute for Surgical Research to automate resuscitation of burn patients. Arcos's product is the first decision support system for automated fluid resuscitation to receive 510(k) clearance from the FDA.

With an investment of $250K by Fannin Innovation Studio, I took on the challenge of leading the launch of a Class I, 510(k)-exempt medical device for respiratory care. As CEO, I was responsible for:• Taking the product from prototype to human testing in 6 months• Leading all aspects of the development process including design, manufacturing, IP, regulatory compliance, marketing, and sales• Launching the product to several hospitals in the Texas Medical Center.

Houston, Texas, Us

I joined Fannin to contribute to the commercialization of early-stage life science technologies. In this role, my key focus areas were:• Identifying and evaluating over 30 promising imaging and informatics technologies (primarily EMRs)• Assessing market potential, conducting due diligence, proposing transactions, and creating business plans • Negotiating and closing a deal with Intubix LLC to fund and manage a respiratory care medical device

Phd, Structural And Computational Biology And Molecular Biophysics (Scbmb)

Mba

Ba, Applied Mathematics

Education record